Unlike active SD, MAS is characterized by elevated IFNγ levels, which plays a central role in MAS development and perpetuation, as demonstrated by the efficacy of emapalumab, an anti‐IFNγ monoclonal antibody, in treating MAS.16, 36, 37. The gene discussed is IFNG; the disease is macrophage activation syndrome.